Tolcher A - Search Results

1

A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients with Small Cell Lung Cancer.

Morgensztern D, Ready N, Johnson ML, Dowlati A, Choudhury N, Carbone DP, Schaefer E, Arnold SM, Puri S, Piotrowska Z, Hegde A, Chiang AC, Iams W, Tolcher A, Nosaki K, Kozuki T, Li T, Santana-Davila R, Akamatsu H, Murakami H, Yokouchi H, Wang S, Zha J, Li R, Robinson RR, Hingorani P, Jeng EE, Furqan M. Morgensztern D, et al. Among authors: tolcher a. Clin Cancer Res. 2024 Nov 15;30(22):5042-5052. doi: 10.1158/1078-0432.CCR-24-1547. Clin Cancer Res. 2024. PMID: 39287821 Free PMC article. Clinical Trial.

2

A Phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitor.

Hao D, Hammond LA, Eckhardt SG, Patnaik A, Takimoto CH, Schwartz GH, Goetz AD, Tolcher AW, McCreery HA, Mamun K, Williams JI, Holroyd KJ, Rowinsky EK. Hao D, et al. Among authors: tolcher aw. Clin Cancer Res. 2003 Jul;9(7):2465-71. Clin Cancer Res. 2003. PMID: 12855619 Clinical Trial.

3

A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies.

Garrison MA, Hammond LA, Geyer CE Jr, Schwartz G, Tolcher AW, Smetzer L, Figueroa JA, Ducharme M, Coyle J, Takimoto CH, De Jager RL, Rowinsky EK. Garrison MA, et al. Among authors: tolcher aw. Clin Cancer Res. 2003 Jul;9(7):2527-37. Clin Cancer Res. 2003. PMID: 12855627 Clinical Trial.

4

A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.

Tolcher AW, Kuhn J, Schwartz G, Patnaik A, Hammond LA, Thompson I, Fingert H, Bushnell D, Malik S, Kreisberg J, Izbicka E, Smetzer L, Rowinsky EK. Tolcher AW, et al. Clin Cancer Res. 2004 Aug 1;10(15):5048-57. doi: 10.1158/1078-0432.CCR-03-0701. Clin Cancer Res. 2004. PMID: 15297406 Clinical Trial.

5

A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties.

Syed S, Takimoto C, Hidalgo M, Rizzo J, Kuhn JG, Hammond LA, Schwartz G, Tolcher A, Patnaik A, Eckhardt SG, Rowinsky EK. Syed S, et al. Among authors: tolcher a. Clin Cancer Res. 2004 Oct 1;10(19):6512-21. doi: 10.1158/1078-0432.CCR-04-0804. Clin Cancer Res. 2004. PMID: 15475438 Clinical Trial.

6

ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas.

de Bono JS, Tolcher AW, Forero A, Vanhove GF, Takimoto C, Bauer RJ, Hammond LA, Patnaik A, White ML, Shen S, Khazaeli MB, Rowinsky EK, LoBuglio AF. de Bono JS, et al. Among authors: tolcher aw. Clin Cancer Res. 2004 Nov 15;10(22):7555-65. doi: 10.1158/1078-0432.CCR-04-0729. Clin Cancer Res. 2004. PMID: 15569986 Clinical Trial.

7

A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer.

Tolcher AW, Chi K, Kuhn J, Gleave M, Patnaik A, Takimoto C, Schwartz G, Thompson I, Berg K, D'Aloisio S, Murray N, Frankel SR, Izbicka E, Rowinsky E. Tolcher AW, et al. Clin Cancer Res. 2005 May 15;11(10):3854-61. doi: 10.1158/1078-0432.CCR-04-2145. Clin Cancer Res. 2005. PMID: 15897586 Clinical Trial.

8

Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas.

Posey JA 3rd, Saif MW, Carlisle R, Goetz A, Rizzo J, Stevenson S, Rudoltz MS, Kwiatek J, Simmons P, Rowinsky EK, Takimoto CH, Tolcher AW. Posey JA 3rd, et al. Among authors: tolcher aw. Clin Cancer Res. 2005 Nov 1;11(21):7866-71. doi: 10.1158/1078-0432.CCR-05-0783. Clin Cancer Res. 2005. PMID: 16278410 Clinical Trial.

9

Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumors.

Ricart AD, Hammond LA, Kuhn JG, Takimoto CH, Goetz A, Forouzesh B, Forero L, Ochoa-Bayona JL, Berg K, Tolcher AW, Rowinsky EK. Ricart AD, et al. Among authors: tolcher aw. Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8728-36. doi: 10.1158/1078-0432.CCR-05-1572. Clin Cancer Res. 2005. PMID: 16361560 Clinical Trial.

10

First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors.

Munster PN, Britten CD, Mita M, Gelmon K, Minton SE, Moulder S, Slamon DJ, Guo F, Letrent SP, Denis L, Tolcher AW. Munster PN, et al. Clin Cancer Res. 2007 Feb 15;13(4):1238-45. doi: 10.1158/1078-0432.CCR-06-1539. Clin Cancer Res. 2007. PMID: 17317835 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

216 results

Search Page

Filters